The Food and Drug Administration (FDA) has posted a discontinuation notice for Thyrolar (liotrix; Allergan) tablets, USP, ¼, ½, 1, 2, and 3 grains. The manufacturing discontinuation was a business decision made by the Company.
Thyrolar contains triiodothyronine (T3 liothyronine) and tetraiodothyronine (T4 levothyroxine) and is indicated as replacement or supplemental therapy in patients with hypothyroidism, and as a pituitary thyroid stimulating hormone (TSH) suppressant, in the treatment or prevention of various types of euthyroid goiters, and in the management of thyroid cancer.
For more information call (800) 678-1605 or visit FDA.gov.
This article originally appeared on MPR